Treatment
Table 3. Biologic Agents for CRSwNP
Agent
Brand Name Type Indication
Benralizumab
FASENRA
Interleukin-5 receptor alpha-
directed cytolytic monoclonal
antibody (IgG1, kappa)
Add-on maintenance
treatment of patients with
severe asthma aged 12
years and older and with an
eosinophilic phenotype
Dupilumab
DUPIXENT
Interleukin-4 receptor alpha
antagonist
Add-on maintenance
treatment in adult patients
with inadequately controlled
CRSwNP
a
Mepolizumab
NUCALA
Interleukin-5 (IL-5) antagonist
monoclonal antibody (IgG1 kappa)
Add-on maintenance
treatment of adult patients
18 years and older with
CRSwNP
b
Omalizumab
XOLAIR
XOLAIR PFS
Anti- IgE antibody Add-on maintenance in adult
patients 18 years of age and
older with CRSwNP
c
a
Also indicated for atopic dermatitis, asthma, eosinophilic esophagitis and prurigo nodularis.
b
Also indicated for eosinophilic asthma, eosinophilic granulomatosis with polyangiitis and
hypereosinophilic syndrome.
c
Also indicated for moderate to severe persistent asthma and chronic spontaneous urticaria (CSU).
